- Assaduab O, Askarian M, Stadler M, et al. Prevalence of vancomycin-resistant enterococci
colonization and risk factors in chronic hemodialysis patients in Shiraz, Iran. BMC Infect Dis 2007;
7:52. - Oliver CN, Blake RK, Steed LL, et al. Risk of vancomycin-resistant Enterococcus (VRE) bloodstream
infection among patients colonized with VRE. Infect Control Hosp Epidemiol 2008; 29:404–409. - Kolar M, Urbanek K, Vagnerova I, et al. The influence of antibiotic use on the occurrence of
vancomycin-resistant enterococci. J Clin Pharm Ther 2006; 31:67–72. - Paterson DL, Muto CA, Ndirangu M, et al. Acquisition of rectal colonization by vancomcyin-resistant
Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those
receiving cefepime-containing antibiotic regimens. Antimicrob Agents Chemother 2008; 52:465–469. - Kachroo S, Dao T, Zabaneh F, et al. Tolerance of vancomycin for surgical prophylaxis in patients
undergoing cardiac surgery and incidence of vancomycin-resistant enterococcus colonization. Ann
Pharmacother 2006; 40:381–385. - Brusch JL. Infective Endocarditis. New York: Informa Healthcare, 2007.
- Cunha BA. Positive blood cultures versus bacteremia. Infect Dis Pract 1996; 20:47–48.
- Cunha BA. Intravenous central line infections in critical care. In: Cunha BA, ed. Infectious Diseases in
Critical Care Medicine. 3rd ed. New York, New York: Informa Healthcare, 2009. - Cunha BA. Enterococcal bacteremia. Clinical diagnostic and therapeutic pathway. Antibiot Clin 2007;
11:413–414. - Chou YY, Lin TY, Lin JC, et al. Vancomycin-resistant enterococcal bacteremia: comparison of clinical
features and outcome betweenEnterococcus faeciumandEnterococcus faeclis. J Microbiol Immunol
Infect 2008; 41:124–129. - Erlandson KM, Sun J, Iwen PC, et al. Impact of the more-potent antibiotics quinupristin-dalfopristin
and linezolid on outcome measure of patients with vancomcycin-resistant Enerococcus bacteremia.
Clin Infect Dis 2008; 46:30–36. - Al-Nassir WN, Sethi AK, Li Y, et al. Both oral metronidazole and oral vancomycin promote persistent
overgrowth of vancomcyin-resistant enterococci during treatment ofClostridium difficile-associated
disease. Antimicrob Agents Chemother 2008; 52:2403–2406. - Kvirikadze N, Suseno M, Vescio T, et al. Daptomycin for the treatment of vancomycin resistant
Enterococcus faeciumbacteremia. Scand J Infect Dis 2006; 38:290–292. - Florescu I, Beuran M, Dimov R, et al. Efficacy and safety of tigecycline compared with vancomycin
or linezolid for treatment of serious infections with methicillin-resistantStaphylococcous aureusor
vancomycin-resistant enterococci: a phase 3, multicentre, double-blind randomized study.
J Antimicrob Chemother 2008; 62:17–28. - Patel M, Weinheimer JD, Waites KB, et al. Active surveillance to determine the impact of methicillin-
resistant Staphylococcus aureuscolonization on patients in intensive care units of a Veterans Affairs
Medical Center. Infect Control Hosp Epidemiol 2008; 29:503–509. - Cheng VC, Li IW, Wu AK, et al. Effects of antibiotics on the bacte load of methicillin-resistant
Staphylococcus aureuscolonization in anterior nares. J Hosp Infect 2008; 70:27–34. - Cunha BA. Clinical manifestations and antimicrobial therapy of methicillin resistant Staphylococcus
aureus (MRSA). Clin Microbiol Infect 2005; 11:33–42. - Cunha BA. Simplified clinical approach to community acquired MRSA (CA-MRSA) infections. J Hosp
Infect 2008; 68:271–273. - Cunha BA. The significance of antibiotic false sensitivity testing with in vitro testing. J Chemother
1997; 9:25–35. - Kim SH, Park WB, Lee KD, et al. Outcome of Staphylococcus aureus bacteremia in patients with
eradicable foci versus noneradicable foci. Clin Infect Dis 2003; 37:794–799. - Cunha BA. Persistent S. aureus bacteremia: clinical pathway for diagnosis & treatment. Antibiot Clin
2006; 10(S1):39–46. - Cunha BA. MSSA/MRSA acute bacterial endocarditis (ABE): clinical pathway for diagnosis &
treatment. Antibiot Clin 2006; 10(S1):29–34. - Greenspon AJ, Rhim ES, Mark G, et al. Lead-associated endocarditis: the important role of methicillin-
resistantStaphylococcus aureus.Pacing Clin Electrophysiol 2008; 31:548–553. - Bonoan JT, Cunha BA.S. aureusas a cause of community-acquired pneumonia in patients with
diabetes mellitus. Infect Dis Clin Pract 1999; 8:319–321. - Adam H, McGeer A, Simor A. Fatal case of post-influenza, community-associated MRSA pneumonia
in an Ontario teenager with subsequent familial transmission. Can Commun Dis Rep 2007; 33:45–48. - Centers for Disease Control and Prevention (CDC). Severe methicillin-resistant Staphylococcus
aureus community-acquired pneumonia associated with influenza-Louisiana and Georgia,
December 2006–January 2007. MMWR Morb Mortal Wkly Rep 2007; 56:325–329.
Antimicrobial Therapy of VRE and MRSA in Critical Care 509